IGFBP7 remodels the tumor microenvironment of esophageal squamous cell carcinoma by activating the TGFβ1/SMAD signaling pathway
Xiuqing Li,Ji Zhang,Youshan Wu,Chuntao Ma,Dongying Wei,Lijuan Pan,Liangliang Cai
DOI: https://doi.org/10.3892/ol.2022.13371
2022-06-11
Oncology Letters
Abstract:Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer, and its development, growth, and invasiveness are regulated by the tumor microenvironment (TME). Insulin‐like growth factor‐binding protein‐7 (IGFBP7), which is closely related to various tumors, transforming growth factor‐β1 (TGFβ1), which is a key signal mediator in oncogenesis, α‐smooth muscle actin (α‐SMA), and collagen I are important components of the TME. IGFBP7 can upregulate the expression of TGFβ1 and activate the TGFβ1/SMAD signaling pathway, which leads to an increase in collagen I in hepatic stellate cells (HSCs). However, the contribution of IGFBP7 to TGFβ1 and the TME in the progression of ESCC remains unknown. In the present study, we investigated IGFBP7 expression and its effects on TGFβ1 and the TME in ESCC. A total of 45 patients were divided into three groups: early‐tumor group (n=15), advanced‐tumor group (n=15), and paracancer control group (n=15). The EC109 cell line was cultured and treated with AdIGFBP7 and LvshTGFβ1, and the expression levels of IGFBP7, TGFβ1, α‐SMA, collagen I, and p‐SMAD2/3 were determined by immunohistochemical staining and western blotting analysis. IGFBP7, TGFβ1, α‐SMA, and collagen I were upregulated in the ESCC samples compared with the control samples (P<0.05), and the values peaked in the advanced‐tumor group (P<0.05). Compared with the control group, the TGFβ1, α‐SMA, p‐SMAD2/3, and collagen I proteins were gradually increased from 24 to 72 h in the EC109 cells treated with AdIGFBP7 (P<0.05). Inhibition of TGFβ1 expression in the EC109 cells treated with AdIGFBP7 gradually reduced the expression of α‐SMA, collagen I, and p‐SMAD2/3 from 24 to 72 h (P<0.05). These findings suggest that increased IGFBP7 may accelerate the progression of ESCC by upregulating TGFβ1, α‐SMA, and collagen I via activating the TGFβ1/SMAD signaling pathway, which could remodel the TME.
oncology